Quoin pharmaceuticals provides corporate update and announces first quarter 2023 financial results

First patient dosed in quoin's single arm, open label clinical trial in netherton syndrome patients currently receiving off-label systemic therapy
QNRX Ratings Summary
QNRX Quant Ranking